Losartan Potassium
Product Images NDC 66336-665

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 66336-665). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Ndc 66336-0665-xx (Ndc 66336 0665 Xx Teva)

Ndc 66336-0665-xx (Ndc 66336 0665 Xx Teva)
This is a bulk source data for medications manufactured for Teva Pharmaceuticals in Sellersville, PA. One of the products is a green oval-shaped film-coated tablet with a 93/7365 imprint and NDC number 00093-7365-10. The medication should be dispensed in a tight and light-resistant container and taken orally according to a physician's advice, warning of possible dizziness, and drowsiness. Another product is Losartan Potassium 50mg in tablet form with NDC 66336-0665-XX and a unique product number of 685-XX. It contains FD&C Yellow No. 6 and is only for use under medical supervision. It should be kept out of reach of children and stored at temperatures between 68°-77° F, with an expiry date of 00-00. There are multiple lots with different RX# numbers.*
FDA Label Image

Ndc 66336-0666-xx (Ndc 66336 0666 Xx Teva)

Ndc 66336-0666-xx (Ndc 66336 0666 Xx Teva)
This is a bulk source data sheet for Losartan Potassium 25mg tablets manufactured for Teva Pharmaceuticals USA. The tablets are green, oval-shaped, and film-coated with markings 93/7364. The tablets are dispensed in a tight and light resistant container, and each contains Losartan Potassium USP at 25 mg strength. The sheet includes product information such as lot numbers, expiration dates, and Rx numbers, and also includes a warning to keep medications out of children's reach and to store them within a specific temperature range.*
FDA Label Image

Chem Structure For Losartan Potassium (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 01)

Chem Structure For Losartan Potassium (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 01)
FDA Label Image

Figure 1 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 02)

Figure 1 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 02)
This text seems to be a result of a study where two medications - Atenolol and Losartan potassium - were tested on patients with a primary endpoint. The study was conducted for 66 months and the adjusted risk reduction was 13% with a p-value of 0.021. It is not clear what the primary endpoint refers to or what condition is being treated.*
FDA Label Image

Figure 2 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 03)

Figure 2 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 03)
This is a study that compares the effectiveness of Atenolol and Losartan Potassium in reducing the risk of fatal and non-fatal stroke. The data shows an adjusted risk reduction of 25% with a p-value of 0.001. The study was conducted for 66 months, with data collected at various intervals from month 6 to month 66.*
FDA Label Image

Figure 3 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 04)

Figure 3 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 04)
FDA Label Image

Figure 4 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 05)

Figure 4 (B1af6b4b 2a05 41d3 Bc65 F6b83f6daa92 05)
This text appears to be a chart or graph comparing the risk reduction percentage of patients who had an event while taking Losartan Potassium versus a placebo over a period of 24 months. The chart also includes some data points at 36 and 48 months. The overall reduction was 16.1% with a significance level of p=0.022.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.